H. Lundbeck A/S (HLBBF)
OTCMKTS · Delayed Price · Currency is USD
5.52
0.00 (0.00%)
At close: Aug 12, 2025
H. Lundbeck Revenue
H. Lundbeck had revenue of 6.02B DKK in the quarter ending June 30, 2025, with 10.45% growth. This brings the company's revenue in the last twelve months to 23.52B, up 13.79% year-over-year. In the year 2024, H. Lundbeck had annual revenue of 22.00B with 10.51% growth.
Revenue (ttm)
23.52B DKK
Revenue Growth
+13.79%
P/S Ratio
1.58
Revenue / Employee
4.12M DKK
Employees
5,707
Market Cap
5.84B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
H. Lundbeck News
- 2 months ago - New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Benzinga
- 2 months ago - New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine - Benzinga
- 3 months ago - Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers - Seeking Alpha
- 6 months ago - Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - PRNewsWire
- 8 months ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha
- 10 months ago - Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal - Seeking Alpha
- 11 months ago - Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management - Seeking Alpha
- 11 months ago - NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday - Benzinga